Zhang, Mi-Mi
Tan, Xuan
Zheng, Yong-Bo
Zeng, Na https://orcid.org/0000-0001-9522-918X
Li, Zhe
Horowitz, Mark Abie https://orcid.org/0000-0003-1318-2029
Feng, Xue-Zhu
Wang, Ke
Li, Zi-Yi
Zhu, Wei-Li
Zhou, Xinyu
Xie, Peng https://orcid.org/0000-0002-0081-6048
Zhang, Xiujun
Wang, Yumei
Shi, Jie https://orcid.org/0000-0001-6567-8160
Bao, Yan-Ping https://orcid.org/0000-0002-1881-0939
Lu, Lin https://orcid.org/0000-0003-0742-9072
Li, Su-Xia https://orcid.org/0000-0002-0781-0300
Funding for this research was provided by:
National Natural Science Foundation of China (81871071, 82288101)
Natural Science Foundation of Beijing Municipality (7222109)
National Clinical Research Centre for Mental Disorder (Peking University Sixth Hospital), the key research project of independent exploration in 2021
National Programs for Brain Science and Brain-like Intelligence Technology of China
Article History
Received: 14 February 2024
Revised: 26 September 2024
Accepted: 3 October 2024
First Online: 11 October 2024
Competing interests
: MAH reports being a collaborating investigator on the RELEASE and RELEASE+ trials in Australia, funded by the MRFF and NHMRC, evaluating hyperbolic tapering of antidepressants against care as usual. MAH reports being a co-founder of and consultant to Outro Health Clinic, which aims to provide digital support for patients in the U.S. to help stop no longer needed antidepressant treatment. All the other authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
: All methods in this study were performed in accordance with the relevant guidelines and regulations. This systematic meta-review strictly followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was preregistered on PROSPERO (CRD 42022304659). Because this study is a meta-analysis and systematic review, the informed consent obtained from all participants does not apply to this study.